HPV-16
Showing 1 - 25 of 6,152
HSIL of Cervix Trial in Heze (NWRD08)
Recruiting
- HSIL of Cervix
- NWRD08
-
Heze, Shandong, ChinaHeze Municipal Hospital
Jun 6, 2023
Oropharynx Squamous Cell Carcinoma Trial (HPV16 Ct-DNA dosing)
Not yet recruiting
- Oropharynx Squamous Cell Carcinoma
- HPV16 Ct-DNA dosing
- (no location specified)
Oct 13, 2022
HPV Infection, HPV-Related Cervical Carcinoma Trial (FluBHPVE6E7, Placebo)
Not yet recruiting
- HPV Infection
- HPV-Related Cervical Carcinoma
- FluBHPVE6E7
- Placebo
- (no location specified)
Apr 24, 2023
HPV 16+ Recurrent or Metastatic Cancer Trial (CD8 reduced peripheral blood cells taken from related donors vaccinated against
Not yet recruiting
- HPV 16+ Recurrent or Metastatic Cancer
- CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16
- Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
- (no location specified)
Jun 27, 2022
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Human Papillomavirus (HPV) Infections, High-risk HPV Trial
Recruiting
- Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III)
- +3 more
- Nonavalent HPV vaccine (9vHPV/Gardasil-9™).
-
L'Hospitalet De Llobregat, Catalunya, SpainGynaecology Unit, Bellvitge University Hospital (HUB)
Jan 24, 2023
CIN3, Cervical Intraepithelial Neoplasia, Cervical Intraepithelial Neoplasia Grade 3 Trial in Groningen (Vvax001 therapeutic
Recruiting
- CIN3
- +3 more
- Vvax001 therapeutic cancer vaccine
-
Groningen, NetherlandsUniversity Medical Center Groningen (UMCG)
Aug 23, 2023
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally
Recruiting
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- +5 more
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
- Pembrolizumab
-
Rochester, MinnesotaMayo Clinic in Rochester
Jan 4, 2023
HPV-associated Oropharyngeal Cancer
Recruiting
- PREDICTIVE BIOMARKERS
- +2 more
- HPV-ASSOCIATED OROPHARYNGEAL CANCER
-
Rome, Italy"Regina Elena" National Cancer Institute
Oct 19, 2023
Recurrent Human Papillomavirus Type 16 Associated Cancer Trial in Birmingham, Baltimore (HPV 16 TA-CIN)
Withdrawn
- Recurrent Human Papillomavirus Type 16 Associated Cancer
- HPV 16 TA-CIN
-
Birmingham, Alabama
- +1 more
Nov 29, 2022
CZ Using the Detection of HPV DNA and CINtec Plus
Completed
- Algorithm for Cervix Carcinoma Screening
- HPV DNA test with selective HPV 16/18 genotyping (cobas® 4800 HPV Test, Roche)
- +2 more
-
Praha, Czech Republic, CzechiaAeskulab Patologie, ks
Oct 11, 2022
Human Papillomavirus in Young People Epidemiological Research 3
Not yet recruiting
- Human Papillomavirus Infection
- +6 more
- (no location specified)
Oct 17, 2022
Cervical Carcinoma Trial in Chongqing (TC-E202 cells, IL-2, Fludarabine)
Recruiting
- Cervical Carcinoma
- TC-E202 cells
- +3 more
-
Chongqing, Chongqing, ChinaXiaochun Cheng
Oct 20, 2022
Adult Solid Tumor Trial in Scottsdale, Aurora, Nashville (SQZ-eAPC-HPV, Pembrolizumab)
Recruiting
- Adult Solid Tumor
- SQZ-eAPC-HPV
- Pembrolizumab
-
Scottsdale, Arizona
- +4 more
Jan 26, 2023
Oropharyngeal Cancer, Human Papilloma Virus, Head Neck Cancer Trial (Fludarabine, Cyclophosphamide, NEXI-003 T cells)
Not yet recruiting
- Oropharyngeal Cancer
- +10 more
- Fludarabine
- +2 more
- (no location specified)
Dec 14, 2022
HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer Trial (VB10.16, Atezolizumab Injection [Tecentriq],
Not yet recruiting
- HPV-Related Cervical Carcinoma
- +2 more
- VB10.16
- +2 more
- (no location specified)
Oct 24, 2023
Malignant Tumors of Ill-defined Secondary and Unspecified Sites, Malignant Tumors of Lip Oral Cavity and Pharynx, Oropharyngeal
Terminated
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
- +2 more
- Utomilumab
- ISA101b
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Nov 22, 2022
Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer Trial in United States (RPTR-168)
Terminated
- Head and Neck Squamous Cell Carcinoma
- +2 more
- RPTR-168
-
Scottsdale, Arizona
- +3 more
Dec 2, 2022
Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma Trial in Chicago (HB-201, HB-202, Carboplatin)
Recruiting
- Human Papilloma Virus
- +3 more
- HB-201
- +4 more
-
Chicago, IllinoisUniversity of Chicago
Aug 11, 2022
HPV-Related Squamous Cell Carcinoma, HNSCC Trial in London (VB10.16, Pembrolizumab)
Not yet recruiting
- HPV-Related Squamous Cell Carcinoma
- HNSCC
- VB10.16
- Pembrolizumab
-
London, United KingdomEast and North Hertfordshire NHS Trust Mount Vernon Hospital
Aug 24, 2023
Human Papillomavirus in Young People Epidemiological Research 4
Not yet recruiting
- Human Papillomavirus Infection
- +6 more
- (no location specified)
Oct 17, 2022
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer Trial in Milwaukee (HB-201 IT, HB-201 IV)
Recruiting
- HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
- HB-201 IT
- HB-201 IV
-
Milwaukee, WisconsinFroedtert Hospital and the Medical College of Wisconsin
Jul 28, 2022
Solid Tumors Trial in Houston (ISA 101, Nivolumab)
Completed
- Solid Tumors
- ISA 101
- Nivolumab
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Dec 17, 2021
Cervical Carcinoma, Human Papillomavirus Infection Trial in Liberia (Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis
Enrolling by invitation
- Cervical Carcinoma
- Human Papillomavirus Infection
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
- +3 more
-
Liberia, Guanacaste, Costa RicaAgencia Costarricense de Investigaciones Biomédicas - Fundación
Aug 11, 2022
Adult Solid Tumor Trial in Spain, United States (SQZ-AAC-HPV, Ipilimumab, Nivolumab)
Recruiting
- Adult Solid Tumor
- SQZ-AAC-HPV
- +2 more
-
Duarte, California
- +5 more
Aug 12, 2022